TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06513234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and obinutuzumab
Description: Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
Study: NCT06231277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH002
Description: Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
Study: NCT06630702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS electrode stimulation 1
Description: 300Hz/300us

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS electrode stimulation 2
Description: 130Hz/300us

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS electrode stimulation 3
Description: 60Hz/300us
Study: NCT06631040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti CD19 CAR NK cells
Description: Ten eligible patients with relapsed Acute Lymphoblastic Leukemia will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of anti-CD19 CAR NK cells with close monitoring using one of the following dose levels: • Dose Level 1: 1×10\^7/Kg • Dose Level 2: 5×10\^7/Kg • Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow International Lymphoma Party (LWP) Group guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
Study: NCT03137966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
Study: NCT06084741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations
Description: omitting the intraabdominal drains

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using intraabdominal drains
Description: The investigators will put intraabdominal drains
Study: NCT06196944

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Augmentative Alternative Communication
Description: Traditional Method
Study: NCT06696781

Intervention type: PROCEDURE
Intervention: Pacemaker stimulation
Description: We deactivate the pacemaker to establish baseline measurements of NOL, bispectral index (BIS), mean arterial pressure (MAP), and heart rate (HR), recorded every minute for 5 minutes. We then adjust the pacemaker to 90 bpm and 110 bpm in subsequent 5-minute phases to assess the physiological responses. After deactivating the pacemaker to analyze washout effects, we reactivate it at 110 bpm to observe any changes. A temporary disconnection of the NOL monitor for 1 minute tests system reliability, followed by continued monitoring at the same rate for an additional 5 minutes. Each measurement phase averages data from the last 10 seconds each minute to ensure accuracy and reduce artifacts.
Study: NCT06687785

Intervention type: PROCEDURE
Intervention: Entire Papilla Preservation Technique
Description: A buccal intrasulcular incision was made in the tooth with the defect and a vertical incision was made extending from the buccal center of the tooth to the mesial papillary crest and crossing the mucogingival line. Then, using a micro periosteal elevator, a full-thickness mucoperiosteal flap was lifted from the incision site to the defect under the papilla. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the vertical incision was sutured with 6/0 polypropylene suture using simple suture technique.

Intervention type: PROCEDURE
Intervention: Conventional Flap Surgery Technique
Description: After buccal and lingual intrasulcular incisions were made to eliminate the teeth and papillae adjacent to the defect, a full-thickness mucoperiosteal flap was raised in the vestibular and lingual direction with a periosteal elevator. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the papillary incisions were sutured with 5/0 polypropylene suture using simple suture technique.
Study: NCT06710990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study: NCT06720298

Intervention type: DRUG
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study: NCT05028712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Information Training
Description: Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal training
Description: Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
Study: NCT04783610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol will be administered via oral route.
Study: NCT05899179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Mycobacterium Tuberculosis Fusion Protein
Description: Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Mycobacterium Tuberculosis Fusion Protein
Description: Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Protein Derivative of Tuberculin
Description: Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Protein Derivative of Tuberculin
Description: Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method.
Study: NCT06419933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SuperKids Program
Description: The SuperKids program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment
Study: NCT05235789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rational-Emotive-Behavioral Therapy
Description: The structure of the REBT sessions includes the following points:~1. Determine specific goals that explain what the participant want to achieve through the content of the session.~2. Explain the level of skills to be achieved in each session.~3. Development of the session, reminder of the previous session, review of homework (from the second session to the 8th). Irrational beliefs and disruptive thoughts will be worked on together with the participant in order to achieve an improvement in their emotional state. Key messages with healthier alternatives that make your daily life easier.~4. Establishing homework. Using the REBT Toolbox with Key Messages.~5. Individual psychosocial work will be recorded in the computerized medical history.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group usual care
Description: In the control group, for each center , the depression is treated as usual with the conventional treatment, according to national and international guidelines.
Study: NCT04840862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
Description: Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin 300mg
Description: After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
Study: NCT06196944

Intervention type: OTHER
Group type: OTHER
Intervention: Augmentative Alternative Communication Device
Description: Augmentative Alternative Communication Device 3 session for 40 minutes
Study: NCT05863559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Chef: Family Fun in the Kitchen!
Description: Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
Study: NCT04868864

Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan
Description: Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
Study: NCT06715696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANBIO Gauze (Sterilized, 1% Collagen)
Description: After tissue resection in a standard procedure for gynecological surgery, direct application of HANBIO Gauze to cover the bleeding site/area which identified during dissection.
Study: NCT06705764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tezepelumab
Description: Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90

Intervention type: DRUG
Group type: OTHER
Intervention: Tezepelumab
Description: Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
Study: NCT06732687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics
Description: Calisthenics~Arm Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometrics
Description: Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined( Calisthenics+ Plyometrics)
Description: Description: Both exercises would be performed. First Calisthenics will be performed and then plyometrics will be performed.
Study: NCT06727331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Placebo syringes of saline and matching volume will be produced by IDS.
Study: NCT06740864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial alternating current stimulation
Description: Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
Study: NCT06735768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS treatment
Description: Brightmind.AI´s rTMS protocol is applied

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Determination of motor hotspot and motor treshold
Description: Determination of motor hotspot and motor treshold

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Determination of motor hotspot and motor treshold
Description: Determination of motor hotspot and motor treshold
Study: NCT06740981

Intervention type: OTHER
Intervention: Food diary
Description: A food and beverage diary will be collected for five days starting from the initiation of noninvasive ventilation, with caloric and protein intake quantified by a Nutrition Physician Specialist.
Study: NCT06740448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea
Description: 200 mL Green Tea

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green Tea
Description: 200 mL Green Tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control (Hot Water)
Description: 200 mL hot water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (Hot Water)
Description: 200 mL hot water
Study: NCT06740916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 81-mg aspirin once daily
Description: 81-mg aspirin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 81-mg aspirin twice daily
Description: 81-mg aspirin twice daily
Study: NCT06739629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insect porridge
Description: Yellow mealworm porridge

Intervention type: OTHER
Group type: OTHER
Intervention: Maize Porridge
Description: Maize porridge
Study: NCT06751160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Dry Needling will be given to group A along with baseline treatment through following protocol:~Patient will be in prone lying. Sterilized disposable dry needles of 0.25\*60mm will be used. Dry needling will be performed on three points on Hamstring muscle for one minute each. We considered a line between ischial tuberosity and head of fibula to target long head of bicep femoris (60% of line) and short head of bicep femoris (30% of line). Semitendinosus and Semi Membranosus were targeted at a point of 60% of line from ischial tuberosity to medial epicondyl of femur.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Soft Tissue Mobilization will be given to Group B along with Baseline treatment.~Subject will be in prone lying position with knee bent at 30 to 60 degrees. Soft tissue mobilization will be applied on hamstring muscle through Graston technique. Massage cream will be applied on hamstring muscle and Graston Instrument will be rubbed from gluteal line to politeal fossa 30 times for 60 seconds.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks.
Study: NCT06748521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP + X
Description: Eligible participants will receive 1 cycle of R-CHOP therapy with genotyping and ctDNA testing at C1D14. Chemotherapy sensitive patients with C1D14 ctDNA negative or ctDNA LFC ≥ 2 will continue to receive R-CHOP therapy for up to 6 courses. Potentially resistant patients with C1D14 ctDNA positive and LFC \< 2 were stratified by DLBCL genotyping and treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.
Study: NCT06748612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine
Description: Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentavalent vaccine
Description: Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine
Description: Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated polioviruses to all three poliovirus types: type 1 , 2 and 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine
Description: Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated polioviruses to all three poliovirus types: type 1 , 2 and 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Description: one dose of IPV (0.5 mL) contains inactivated polioviruses to all three poliovirus types: type 1, 2 and 3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent oral polio vaccine (bOPV)
Description: Contain two poliovirus types: type 1 and 3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fractional IPV( fIPV)
Description: The dose of fIPV is 0.1 mL or 1/5th of a full dose
Study: NCT06749834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Description: 1. Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，or intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg).~2. Patients within 4.5-9 hours of onset with core/perfusion mismatch confirmed by CTP/MRI, is treated with alteplase for intravenous thrombolysis.
Study: NCT06751004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALLISTIC SIX EXERCISES
Description: Ballistic six exercises will be given to group A and exercises of 3 sets of 10-20 repetitions will be completed, with each series offering 30-60 seconds of rest. The ballistic Six exercise uses resistance-band latex tube and fitness balls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESISTANCE-BAND EXERCISES
Description: Resistance-band exercises will be given to group B and the duration of training sessions will be 3 sets of 10-20 repetitions
Study: NCT06750497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Description: Two days of forearm immobilization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Description: Two days of forearm immobilization
Study: NCT06749847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Women receive invitation letter with HPV self-sampling kit
Description: Direct mailing of HPV self-sampling kit. Women receive HPV self-sampling kit with instructions. SMS reminder at 3 months if no participation. Assistance provided for triage cytology if HPV positive.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Women receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider
Description: Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation.
Study: NCT06750120

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Family food ration
Description: Monthly household food rations providing 5 daily food groups and a mean of 165 kcal/per capita/day